1. Abraham I, Harrington AR, Bootman JL (2013) The QALY controversy in the United States. Invited presentation at the EU Special Conference “Health Outcomes in Europe: the QALY controversy. New European Guidelines in Cost-Effectiveness Assessment”. Available from:
http://www.echoutcome.eu/images/stories/Abraham_QALY_Controversy_in_US.pdf
(Accessed 28 December 2014).
2. American College of Surgeons (2013) National cancer data base public benchmarks. Available from:
https://cromwell.facs.org/BMarks/BMPub/ver10/Docs
(Accessed 28 December 2014).
3. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg M, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413.
4. Cancer Research UK (2012) Pancreatic cancer survival statistics. Available from:
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/pancreas/survival/
(Accessed 28 December 2014).
5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX vs gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817–1825.